Deep-pocketed investors have adopted a bearish approach towards Regeneron Pharmaceuticals REGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in REGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Regeneron Pharmaceuticals. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 50% bearish. Among these notable options, 2 are puts, totaling $122,000, and 6 are calls, amounting to $240,350.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $530.0 and $1095.0 for Regeneron Pharmaceuticals, spanning the last three months.
Insights into Volume & Open Interest
In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 92.17 with a total volume of 41.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Regeneron Pharmaceuticals's big money trades within a strike price range of $530.0 to $1095.0 over the last 30 days.
Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN | PUT | TRADE | BEARISH | 12/18/26 | $122.0 | $119.0 | $122.0 | $950.00 | $61.0K | 55 | 10 |
| REGN | PUT | TRADE | BEARISH | 12/18/26 | $122.0 | $118.0 | $122.0 | $950.00 | $61.0K | 55 | 5 |
| REGN | CALL | TRADE | NEUTRAL | 05/16/25 | $38.4 | $33.1 | $35.4 | $1095.00 | $49.5K | 15 | 14 |
| REGN | CALL | TRADE | BULLISH | 12/18/26 | $483.1 | $473.1 | $483.1 | $530.00 | $48.3K | 3 | 0 |
| REGN | CALL | TRADE | NEUTRAL | 02/21/25 | $96.1 | $88.3 | $91.9 | $920.00 | $45.9K | 17 | 5 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Where Is Regeneron Pharmaceuticals Standing Right Now?
- Currently trading with a volume of 96,123, the REGN's price is down by -2.34%, now at $939.78.
- RSI readings suggest the stock is currently may be oversold.
- Anticipated earnings release is in 8 days.
What Analysts Are Saying About Regeneron Pharmaceuticals
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1155.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from Leerink Partners has revised its rating downward to Market Perform, adjusting the price target to $1077. * An analyst from Truist Securities has decided to maintain their Buy rating on Regeneron Pharmaceuticals, which currently sits at a price target of $1137. * An analyst from Wells Fargo persists with their Overweight rating on Regeneron Pharmaceuticals, maintaining a target price of $1050. * Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $1260. * An analyst from RBC Capital persists with their Outperform rating on Regeneron Pharmaceuticals, maintaining a target price of $1252.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
